Document Detail


Flecainide for supraventricular tachycardia in children.
MedLine Citation:
PMID:  3136635     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The clinical efficacy, adverse effects and pharmacokinetics of flecainide were evaluated in 16 pediatric and young adult patients with supraventricular tachycardia (SVT). Patients had received an average of 2.8 drugs before flecainide was tried. The following mechanisms of supraventricular arrhythmias were determined in patients by intracardiac electrophysiologic studies: atrioventricular node reentry, 4; reentry through an accessory connection, 7; atrial automatic focus, 2; atrial flutter, 3. Twelve patients had normal cardiac anatomy and 4 had congenital heart disease. Each patient received 2.8 mg/kg/day of flecainide divided into 2 doses 12 hours apart. After 3 days, the dose was increased to 5.6 mg/kg/day if necessary. In 14 patients, serum flecainide concentrations measured 3 to 4 days after beginning therapy ranged from 0.1 to 0.8 micrograms/ml (mean 0.40). Flecainide successfully controlled SVT in 8 of 16 patients. SVT in 3 of 7 patients with accessory connections and in 3 of 4 patients with atrioventricular node reentry was successfully controlled. In 1 of 2 patients with atrial automatic tachycardia, SVT had been completely controlled over 16 months. Only 1 of 3 patients treated for atrial flutter responded. Follow-up for successfully treated patients ranged from 4 to 16 months (median 9). Seven patients continue to take flecainide. None of the patients had clinical congestive heart failure. No drug-related adverse effects were noted on the resting surface electrocardiogram. Flecainide rarely produced proarrhythmic effects in this series. The 2 that were observed were mild and caused no clinical problems. Noncardiovascular side effects also occurred infrequently.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
V Zeigler; P C Gillette; B Hammill; B A Ross; L Ewing
Related Documents :
6862705 - Limiting factor for the initiation of reentrant tachycardia in concealed wolff-parkinso...
14712325 - Stroke prevention in hospitalized patients with atrial fibrillation: a population-based...
7754955 - Transesophageal echocardiographic guidance of cardioversion in patients with atrial fib...
8993265 - Right-to-left interatrial shunt after pneumonectomy.
11021505 - Voice-related quality of life (v-rqol) following type i thyroplasty for unilateral voca...
20602045 - Headache precipitated by valsalva maneuvers in patients with congenital chiari i malfor...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  62     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1988 Aug 
Date Detail:
Created Date:  1988-09-22     Completed Date:  1988-09-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  41D-43D     Citation Subset:  AIM; IM    
Affiliation:
South Carolina Children's Heart Center, Medical University of South Carolina, Charleston 29425.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Flecainide / administration & dosage,  therapeutic use*
Follow-Up Studies
Humans
Tachycardia, Supraventricular / drug therapy*
Time Factors
Chemical
Reg. No./Substance:
54143-55-4/Flecainide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Restoration of sinus rhythm with flecainide in patients with atrial fibrillation.
Next Document:  Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricul...